share_log

Ningbo David Medical Device (SZSE:300314) Jumps 24% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns

Ningbo David Medical Device (SZSE:300314) Jumps 24% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns

宁波大卫医疗器械(深圳证券交易所代码:300314)本周上涨24%,尽管收益增长仍落后于五年股东回报
Simply Wall St ·  05/08 18:03

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. For example, long term Ningbo David Medical Device Co., Ltd. (SZSE:300314) shareholders have enjoyed a 57% share price rise over the last half decade, well in excess of the market return of around 14% (not including dividends).

一般而言,积极选股的目的是寻找回报优于市场平均水平的公司。收购被低估的企业是获得超额回报的一种途径。例如,宁波戴维医疗器械有限公司(深交所股票代码:300314)的长期股东在过去五年中股价上涨了57%,远远超过了约14%的市场回报率(不包括股息)。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在过去一周强劲上涨之后,值得一看的是长期回报是否是由基本面改善推动的。

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

用本杰明·格雷厄姆的话来说:从短期来看,市场是一台投票机器,但从长远来看,它是一台称重机。研究市场情绪如何随着时间的推移而变化的一种方法是研究公司股价与其每股收益(EPS)之间的相互作用。

During five years of share price growth, Ningbo David Medical Device achieved compound earnings per share (EPS) growth of 43% per year. The EPS growth is more impressive than the yearly share price gain of 9% over the same period. So one could conclude that the broader market has become more cautious towards the stock.

在五年的股价增长中,宁波戴维医疗器械实现了每年43%的复合每股收益(EPS)增长。每股收益的增长比同期9%的年度股价增长更令人印象深刻。因此,人们可以得出结论,整个市场对该股变得更加谨慎。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下图中看到 EPS 随时间推移的变化(点击图表查看确切值)。

earnings-per-share-growth
SZSE:300314 Earnings Per Share Growth May 8th 2024
SZSE: 300314 每股收益增长 2024 年 5 月 8 日

This free interactive report on Ningbo David Medical Device's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

如果你想进一步调查该股,这份关于宁波戴维医疗器械收益、收入和现金流的免费互动报告是一个很好的起点。

What About Dividends?

分红呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Ningbo David Medical Device, it has a TSR of 64% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

重要的是要考虑任何给定股票的股东总回报率和股价回报率。股东总回报率是一种回报计算方法,它考虑了现金分红的价值(假设收到的任何股息都经过再投资)以及任何贴现资本筹集和分拆的计算价值。因此,对于支付丰厚股息的公司来说,股东总回报率通常远高于股价回报率。以宁波戴维医疗器械为例,在过去的5年中,其股东回报率为64%。这超过了我们之前提到的其股价回报率。这在很大程度上是其股息支付的结果!

A Different Perspective

不同的视角

We regret to report that Ningbo David Medical Device shareholders are down 29% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 8.9%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 10% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Ningbo David Medical Device better, we need to consider many other factors. To that end, you should learn about the 2 warning signs we've spotted with Ningbo David Medical Device (including 1 which is significant) .

我们遗憾地报告,宁波戴维医疗器械的股东今年下跌了29%(甚至包括股息)。不幸的是,这比整个市场8.9%的跌幅还要严重。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。好的一面是,长期股东赚了钱,在过去的五年中,每年增长10%。如果基本面数据继续显示长期可持续增长,那么当前的抛售可能是一个值得考虑的机会。长期跟踪股价表现总是很有意思的。但是,要更好地了解宁波戴维医疗器械,我们需要考虑许多其他因素。为此,你应该了解我们在宁波戴维医疗器械上发现的两个警告信号(包括一个重要的警告信号)。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果你想看看另一家公司——一家财务状况可能优异的公司——那么千万不要错过这份已经证明自己可以增加收益的公司的免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发